Outcomes of second-trimester pregnancy terminations with misoprostol: Comparing 2 regimens

Rodney K. Edwards, Shireen M. Sims, Lawrence Devoe

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Objective: The purpose of this study was compare outcomes of second-trimester pregnancy terminations with misoprostol between our previous low- (200 μg every 12 h) and present high-dose (400 μg every 6 h) regimens. Study design: This was an historic cohort study that was conducted from June 1996 to February 2004 on women undergoing medical termination of pregnancy at 13 to 27 weeks. Exclusion criteria were multiple gestation, placenta previa, and primary use of another medication. Results: The cohort consisted of 147 women. For the low- (n = 100) and high-dose (n = 47) groups, respectively, median times to delivery were 22.5 vs 13.25 hours (P = .001). More patients in the high-dose group were delivered vaginally within 24 (81% vs 54%; P = .002) and 48 hours (98% vs 84%; P = .014). Fewer patients in the high-dose group required a second abortifacient (6% vs 27%; P = .004). Clinical chorioamnionitis was more common in the high-dose group (P = .03). One patient experienced a uterine rupture and is included in the analysis. Side effects were uncommon and did not differ between groups. Conclusion: Our present high-dose regimen for misoprostol terminations of pregnancy effects delivery more rapidly without an appreciable increase in side effects or complications.

Original languageEnglish (US)
Pages (from-to)544-548
Number of pages5
JournalAmerican journal of obstetrics and gynecology
Volume193
Issue number2
DOIs
StatePublished - Aug 2005
Externally publishedYes

Keywords

  • Misoprostol
  • Pregnancy
  • Pregnancy termination
  • Second trimester

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Outcomes of second-trimester pregnancy terminations with misoprostol: Comparing 2 regimens'. Together they form a unique fingerprint.

Cite this